DICE Therapeutics, Inc.
DICE Therapeutics, Inc. (DICE): 2 pipeline candidates · ~53 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
53.2 months
D/E 0.06
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for DICE Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$73.7M
Quarterly Burn
$28.6M
Runway
53.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in DICE Therapeutics, Inc.'s pipeline?
DICE Therapeutics, Inc. (DICE) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is DICE Therapeutics, Inc.'s lead drug candidate?
DICE Therapeutics, Inc.'s most advanced tracked candidate is dc-806 (Phase 2) for psoriasis.
What is DICE Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, DICE Therapeutics, Inc. has approximately 53.2 months of cash runway.
Who is the CEO of DICE Therapeutics, Inc.?
Kevin Judice, Ph.D. is the chief executive officer of DICE Therapeutics, Inc. (DICE).
Get the full picture on DICE Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.